3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Breast Neoplasms
25
Lymphoma
21
Neutropenia
13
Lymphoma, Large B-Cell, Diffuse
12
Lymphoma, Non-Hodgkin
11
Neoplasms
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Carcinoma, Non-Small-Cell Lung
8
Multiple Myeloma
7
Leukemia
7
Burkitt Lymphoma
7
Ovarian Neoplasms
6
Lymphoma, Follicular
6
Lung Neoplasms
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Urinary Bladder Neoplasms
4
Testicular Neoplasms
4
Sarcoma
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, B-Cell, Marginal Zone
4
Hodgkin Disease
4
Central Nervous System Neoplasms
4
Testicular Germ Cell Tumor
3
Teratoma
3
Rhabdomyosarcoma
3
Chemotherapy-induced Neutropenia
3
Carcinoma, Ovarian Epithelial
3
Carcinoma, Embryonal
3
Adenocarcinoma, Bronchiolo-Alveolar
3
Interventions
Cyclophosphamide
46
fludarabine phosphate
24
Busulfan
22
Peripheral Blood Stem Cell Transplantation
20
Radiotherapy
19
Filgrastim
19
Mycophenolic Acid
18
Antilymphocyte Serum
18
Cyclosporine
17
Whole-Body Irradiation
16
Rituximab
16
Etoposide
16
Methotrexate
15
Melphalan
15
Methylprednisolone
14
Tacrolimus
12
Cytarabine
12
Vincristine
10
Prednisone
10
Doxorubicin
10
Cord Blood Stem Cell Transplantation
10
Thiotepa
6
Granulocyte Colony-Stimulating Factor
6
Leucovorin
5
sargramostim
4
fludarabine
4
Daunorubicin
4
glofitamab
3
Sirolimus
3
Methylprednisolone Hemisuccinate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Dendritic Cell Sarcoma, Interdigitating
×
pegfilgrastim
×
Clear all
NCT02531308
2022-09-28
DLBCL
Rush University Medical Center
Phase 2
Terminated
5 enrolled
5 charts